The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / July / What Tears Tell Us About Neurological Health
Neurology Point of care testing Technology and innovation

What Tears Tell Us About Neurological Health

An experimental graphene-based device could support future noninvasive neurological biomarker testing from tear samples

07/16/2026 News 2 min read
  • Full Article
  • Summary
  • Listen
  • Scorecard
  • Quiz

Share

Objective:

To explore the development of a low-cost electrochemical sensor for measuring dopamine in tears as a noninvasive method for monitoring neurological biomarkers.

Approach:
  • Sensor Development: Researchers created a sensor using laser-induced graphene modified with nickel nitrate and urea to enhance dopamine detection in tear fluid.
  • Testing Conditions: The sensor was evaluated in buffered laboratory solutions, synthetic tear fluid, and recovery experiments to mimic real-world conditions.
Key Findings:
  • The sensor demonstrated improved electron transfer and detection sites due to modifications, resulting in stronger and more selective responses.
  • It maintained stable function for at least one week post-fabrication and showed reliable responses across clinically relevant dopamine concentrations.
  • Recovery values approached 100 percent, indicating minimal interference from common tear components.
Interpretation:

Further validation in patient samples is required.

Limitations:
  • The sensor has not yet been validated in patient samples.
  • Further studies are needed to confirm correlation with neurological disease status or treatment response.
Conclusion:

The study presents a promising proof of concept for using tear samples in monitoring neurological biomarkers noninvasively.

Sources:
  • ACS Publications

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.